生物活性 靶点 体外研究 体内研究 CS-2259 试剂级价格
  • 首页
  • 个人中心
  • 委托采购
  • 采购清单
ChemicalBook  CAS数据库列表  CS-2259

CS-2259

生物活性 靶点 体外研究 体内研究 CS-2259 试剂级价格
CS-2259,1421693-22-2,结构式
CS-2259
  • CAS号:1421693-22-2
  • 英文名:CDKI-73
  • 中文名:CS-2259
  • CBNumber:CB53034461
  • 分子式:C15H15FN6O2S2
  • 分子量:394.45
  • MOL File:1421693-22-2.mol
CS-2259化学性质
  • 沸点 :642.9±65.0 °C(Predicted)
  • 密度 :1.524±0.06 g/cm3(Predicted)
  • 储存条件 :Store at -20°C
  • 溶解度 :DMSO:52.0(Max Conc. mg/mL);131.83(Max Conc. mM)
  • 形态 :Solid
  • 酸度系数(pKa) :10.06±0.60(Predicted)
  • 颜色 :Light yellow to yellow

CS-2259性质、用途与生产工艺

  • 生物活性 CDKI-73 (LS-007) 是一种有效的 CDK 抑制剂，对CDK1、CDK2、CDK4和CDK9的IC50值分别为8.17 nM，3.27 nM，8.18 nM和5.78 nM。CDKI-73 可诱导癌细胞的凋亡。CDKI-73 是一种口服生物利用型且高效的 CDK9 抑制剂，可用于治疗急性髓细胞性白血病。
  • 靶点
    TargetValue
    CDK2
    (Cell-free assay)     		3.27 nM
    CDK9
    (Cell-free assay)     		5.78 nM
    CDK1
    (Cell-free assay)     		8.17 nM
    CDK4
    (Cell-free assay)     		8.18 nM
  • 体外研究

    CDKI-73 is highly cytotoxic to primary leukemia cells derived from CLL patients (mean LD 50 = 0.08 μM) and shows>500-fold selectivity for primary leukemia cells over normal B-lymphocytes (LD 50 = 40.5 μM).
    CDKI-73 (0.1 μM, 4 h) inhibits the phosphorylation of serine 2 of RNA polymerase II and MCL1 protein expression in CLL cells.
    CDKI-73 induced caspase-dependent apoptosis that was preceded by dephosphorylation of cdk9 and serine 2 of RNA polymerase II.
    CDKI-73 is highly effective against all cell lines tested with an IC 50 in the range of 0.012-0.517 μM; in particular three MLL-AML cell lines, namely MOLM13, MV4-11 and THP-1, were highly sensitive to CDKI-73 with IC 50 values <0.062 μM.

    Cell Viability Assay.

    Cell Line: CLL cells.
    Concentration: 0-1 μM.
    Incubation Time: 48 h.
    Result: Shows preferential cytotoxicity in CLL cells.
  • 体内研究

    CDKI-73 (25, 50, 100 mg/kg) markedly decreases tumor growth in a dose-dependent manner and results in a prolongation of animal life span (P < 0.001) without causing body weight loss and other overt toxicities..

    Animal Model: MV4-11 tumor bearing mice.
    Dosage: 25 mg/kg.
    Administration: Orally once everyday for 33 days.
    Result: Caused a remarkable delay in tumor growth compared to vehicle-treated mice, as reflected in a percentage for the mean tumor volume in treated to control mice of 43% at day 31.
    Animal Model: Balb/C mice aged 6-8 weeks.
    Dosage: 2 mg/kg (IV), 10, 20 and 40 mg/kg (PO). (Pharmacokinetic Analysis.)
    Administration: IV and PO, single dose.
    Result: The C max increased from 1.29 to 3.66 μM at a mean time of 1 h and the area under the curve (AUC) of CDKI-73 increased from 3.51 to 12.8 μM.h when the oral dose was escalated from 10 to 40 mg/kg.
    CDKI-73 was eliminated from plasma with a mean terminal half-life (T1/2) of 2 h. Its oral bioavailability (F) ranged from 54 to 85% across the three doses.
CS-2259上下游产品信息
上游原料
下游产品
CS-2259 试剂级价格
  • 更新日期：2024/11/08
  • 产品编号：HY-12445
  • 产品名称：Asnuciclib
  • CAS编号：
  • 包装：1 mg
  • 价格：1600元
  • 更新日期：2024/11/08
  • 产品编号：HY-12445
  • 产品名称：CS-2259 CDKI-73
  • CAS编号：1421693-22-2
  • 包装：2mg
  • 价格：2333元
CS-2259生产厂家
  • 公司名称：上海超岚化工科技中心
  • 联系电话：021-QQ：65489617 15618227136
  • 电子邮件：Sales@ATKchemical.com
  • 国家：中国
  • 产品数：7267
  • 优势度：58
关注Chemicalbook 进入官方账号